The IMBG has been clinically tested in the renal transplantation maintenance period (after >1 year post RT). The reason is that currently the major challenge for clinicians is to improve the graft survival after one year, reducing the risk of chronic allograft injury due to rejection and avoiding at the same time immunosuppressive adverse effects like infections and malignancies. Graft survival during first year has reached very good results.
That´s why the IS tested in IMBG are Tacrolimus, Cyclosporin, Mycophenolate, Sirolimus, Everolimus, Azathioprine and Methylprednisolone, which are the ones used for renal maintenance therapy in clinical practice.
It is planned to test the use of the IMBG in patients just before transplantation in the near future. The inclusion of the IL-2 inhibitor products will be approached in this phase of IMBG development.
